Glucagon‐like pepetide‐1 receptor agonist suggests novel therapeutic options for hypothalamic obesity
Authors:
Open Access
- 11 December 2024
- journal article
- research article
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (3) , 357-359
Abstract
We briefly summarizes the mechanism of GLP-1RA therapy in HO both in rodents and in humans. We also summarized the clinical trials and case reports of GLP-1RA therapy in HO, especially the more and more often used semaglutide. We are hoping the therapy of GLP-1RA in HO will arouse more attention from clinicians in the future.Keywords
This publication has 15 references indexed in Scilit:
- Evaluating the effectiveness and underlying mechanisms of incretin-based treatments for hypothalamic obesity: A narrative reviewObesity Pillars, 2024
- Liraglutide for Weight Management in Children and Adolescents With Prader–Willi Syndrome and ObesityThe Journal of Clinical Endocrinology & Metabolism, 2022
- Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonistInternational Journal of Obesity, 2022
- MRI measures of hypothalamic injury are associated with glucagon‐like peptide‐1 receptor agonist treatment response in people with hypothalamic obesityDiabetes, Obesity and Metabolism, 2021
- A phase 3 randomized clinical trial using a o nce‐weekly glucagon‐like peptide‐1 receptor agonist in adolescents and young adults with hypothalamic obesityDiabetes, Obesity and Metabolism, 2020
- GLP-1 and weight loss: unraveling the diverse neural circuitryAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2016
- Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes PatientsThe Journal of Clinical Endocrinology & Metabolism, 2016
- Excess Mortality and Morbidity in Patients with Craniopharyngioma, Especially in Patients with Childhood Onset: A Population-Based Study in SwedenThe Journal of Clinical Endocrinology & Metabolism, 2015
- PVN infusion of GLP-1-(7—36) amide suppresses feeding but does not induce aversion or alter locomotion in ratsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 1998
- A role for glucagon-like peptide-1 in the central regulation of feedingNature, 1996